Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings.
Vol 23, No 16S (June 1 Supplement), 2005: 7014
© 2005 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Albain, K. S. Search for Related Content PubMed Articles by Albain, K. S.

Abstract

Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309)

Loyola Univ Chicago Med Ctr, Maywood, IL; Radiation Therapy Oncology Group, Philadelphia, PA; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Wayne State University/Karmanos Cancer Ctr, Detroit, MI; Princess Margaret Hosp, Toronto, ON, Canada; Tom Baker Cancer Ctr, Calgary, AB, Canada; UC Davis Cancer Ctr, Sacramento, CA; Vanderbilt-Ingram Cancer Ctr, Nashville, TN; Medcl Univ of South Carolina, Charleston, SC; Mayo Clinic, Rochester, MN

7014

Background: Surgery after CT/RT remains controversial for patients (pts) with stage IIIA(pN2) NSCLC. Initial analyses of INT 0139 showed significantly better progression-free survival (PFS), but not overall survival (OS), in the trimodality arm. (PASCO 2003) With longer follow-up (2.5 yrs per pt), new analyses of primary endpoints PFS and OS were conducted. Methods: Pts with PS 0–1 and T1–3, pN2, M0 NSCLC were randomized if resection was technically feasible. All received cisplatin 50 mg/m2 d1, 8, 29, 36 and etoposide 50 mg/m2 d1–5, d29–33 (PE) and RT to 45 Gy starting day 1. Arm 1 had resection if no progression (PD), then PE X2; Arm 2 completed RT to 61 Gy with PE X2. Intent to treat analyses used Kaplan-Meier estimates, log-rank tests and Cox multivariate models; exploratory analyses used logistic regression. All CI are 95% and p-values, 2-sided. Results: 396 eligible pts were enrolled (Arm 1, 202; Arm 2, 194; well-balanced on all factors). Treatment-related deaths: Arm 1, 16 (7.9%), of which 10 (5.0%) were within 30 days postop; Arm 2, 4 (2.1%). Deaths by type of surgery: 5/23 (22%) simple and 9/31 (29%) complex pneumonectomies, 1/98 (1%) lobectomies. Arm 1 pathology (n=164): T0N0, 29 (18%); TanyN0, 76 (46%). Arm 1 PFS is superior: median 12.8 vs 10.5 mos, p=0.017, HR 0.77 (0.62, 0.96); 5-yr 22.4% vs 11.1%. More pts on Arm 1 are alive without PD (p=0.008), but more died without PD (p=0.021). OS curves overlap for 2 yrs, but separate late favoring Arm 1: median 23.6 vs 22.2 mos, p=0.24, HR 0.87 (0.70,1.10); 5-yr 27.2% vs 20.3%, odds ratio for 5-yr survival 0.63 (0.36, 1.10, p=0.10). 96 pts are alive/censored. Independent favorable OS predictors: female, no weight loss. Arm 1 5-yr OS if pN0 at surgery was 41%; pN1–3, 24%; no surgery, 8% (p< 0.0001). Conclusions: 1) Longer follow-up of INT 0139 confirms significantly improved PFS but not OS when surgery follows CT/RT in pts with stage IIIA(pN2) NSCLC, 2) there is a trend for better 5-yr OS with trimodality therapy, 3) pN0 at surgery predicts long-term survival, 4) surgery after CT/RT can be considered in fit pts, 4) this approach may not be optimal if a pneumonectomy is needed.

No significant financial relationships to disclose.

Abstract presentation from the 2005 ASCO Annual Meeting